Private equity firm acquires Welsh CRO Simbec-Orion for undisclosed price

handshake
The CBPE deal for Simbec-Orion will provide funding for international expansion for the CRO, particularly in the U.S. and European markets. (Pixabay/geralt)

Welsh CRO Simbec-Orion was acquired by U.K.-based private equity firm CBPE Capital for an undisclosed price.

The acquisition, which was made via a management buyout through CPBE’s Capital Fund IX, acquired the shareholding of the Wales Life Sciences Investment Fund (WLSIF) that was managed by Arix Capital Management, a subsidiary of Arix Bioscience, the company said. The CRO was formed in 2014 with the merger of Simbec Research and Orion Clinical in a deal funded by WLSIF, which had acquired Simbec in 2013.

The CBPE deal for Simbec-Orion will provide funding for international expansion for the CRO, particularly in the U.S. and European markets.

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

“The combination of Simbec Research and Orion Clinical provided the base to create a growing CRO in the midmarket,” Ronald Openshaw, Simbec-Orion’s chief executive, said in a statement. “We are delighted to secure this return for the WLSIF and have clear plans with CBPE for the future growth of the group.”

Simbec-Orion, which is a full service CRO across all stages of development through phases 1, 2 and 3, focuses on biotech companies and small-cap, specialty and mid-cap pharma companies. Its main concentrations are in oncology, rare diseases and orphan drugs, respiratory conditions and translational medicine.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.